Correlation between hybrid capture II high-risk human papillomavirus DNA test chemiluminescence intensity from cervical samples with follow-up histologic results
dc.contributor.author | Knoepp, Stewart M. | en_US |
dc.contributor.author | Kuebler, Diane L. | en_US |
dc.contributor.author | Wilbur, David C. | en_US |
dc.date.accessioned | 2010-09-02T15:25:08Z | |
dc.date.available | 2011-03-01T16:26:48Z | en_US |
dc.date.issued | 2010-08-25 | en_US |
dc.identifier.citation | Knoepp, Stewart M.; Kuebler, Diane L.; Wilbur, David C. (2010). "Correlation between hybrid capture II high-risk human papillomavirus DNA test chemiluminescence intensity from cervical samples with follow-up histologic results." Cancer Cytopathology 118(4): 209-217. <http://hdl.handle.net/2027.42/77987> | en_US |
dc.identifier.issn | 1934-662X | en_US |
dc.identifier.issn | 1934-6638 | en_US |
dc.identifier.uri | https://hdl.handle.net/2027.42/77987 | |
dc.description.abstract | BACKGROUND: The Hybrid Capture II high-risk human papillomavirus (hrHPV) DNA test is a US Food and Drug Administration-approved nucleic acid hybridization assay using chemiluminescence for the semiquantitative detection of hrHPV in cervical samples. Patient samples and controls are used to calculate results as negative for hrHPV if <1.0, positive for hrHPV if >2.5, and “equivocal” if between 1.0 and 2.5. METHODS: The authors reported on the cervical histologic results of 209 patients demonstrating “equivocal” results for hrHPV from SurePath (204 patients) or ThinPrep (5 patients) vials, and compared patients in this cohort with atypical squamous cells of undetermined significance (ASC-US) cytology on the index cervical Papanicolaou (Pap) test (Group 1; n = 148 patients) with a patient cohort demonstrating unequivocal positive hrHPV test results (Group 2; n = 148 patients). The chemiluminescence intensity of hrHPV tests from patients in Group 2 were correlated with the presence and severity of dysplasia on subsequent histologic results, and patients were thereby stratified for their subsequent risk of cervical intraepithelial neoplasia (CIN) types II/III. RESULTS: Approximately 97% of hrHPV tests demonstrating “equivocal” results were found to be positive at the time of retesting, and 15% of biopsied cases demonstrated CIN II or III. Results of follow-up histology after an ASC-US diagnosis, expressed as a percentage of the biopsied cohort, were: CIN II/III: 16.5% in Group 1 and 22.4% in Group 2; CIN I: 27% in Group 1 and 23.5% in Group 2; and negative: 56.5% in Group 1 and 54.1% in Group 2. Chemiluminescence intensity did not appear to be correlated with the severity of dysplasia. CONCLUSIONS: The percentage of high-grade CIN in the “equivocal” hrHPV cohort is highly significant and therefore the management of these patients should be similar to the unequivocally positive population. After an unequivocal positive hrHPV test, the hrHPV chemiluminescence intensity does not appear to further predict the rate of high-grade CIN. Cancer (Cancer Cytopathol) 2010. © 2010 American Cancer Society. | en_US |
dc.format.extent | 1063233 bytes | |
dc.format.extent | 3118 bytes | |
dc.format.mimetype | application/pdf | |
dc.format.mimetype | text/plain | |
dc.publisher | John Wiley & Sons, Inc. | en_US |
dc.subject.other | Life and Medical Sciences | en_US |
dc.subject.other | Cancer Research, Oncology and Pathology | en_US |
dc.title | Correlation between hybrid capture II high-risk human papillomavirus DNA test chemiluminescence intensity from cervical samples with follow-up histologic results | en_US |
dc.type | Article | en_US |
dc.rights.robots | IndexNoFollow | en_US |
dc.subject.hlbsecondlevel | Oncology and Hematology | en_US |
dc.subject.hlbtoplevel | Health Sciences | en_US |
dc.description.peerreviewed | Peer Reviewed | en_US |
dc.contributor.affiliationum | Department of Pathology, University of Michigan, Ann Arbor, Michigan ; Fax: (734) 763-4095 ; Department of Pathology, University of Michigan, 2G332UH, 1500 East Medical Center Drive, SPC 5054, Ann Arbor, MI 48109 | en_US |
dc.contributor.affiliationother | Department of Pathology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts | en_US |
dc.contributor.affiliationother | Department of Pathology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts | en_US |
dc.identifier.pmid | 20578088 | en_US |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/77987/1/20093_ftp.pdf | |
dc.identifier.doi | 10.1002/cncy.20093 | en_US |
dc.identifier.source | Cancer Cytopathology | en_US |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.